Cytyc invests in endometriosis
This article was originally published in The Gray Sheet
Executive Summary
Women's healthcare firm views a less-invasive, serum-based diagnostic test presently being developed by Valeo Medical for detecting endometriosis as having "excellent potential" to become a successful product. Cytyc announced making an equity investment in Valeo Nov. 9. A Valeo spokesperson says the firm is in preclinical development for the test, having completed feasibility studies on more than 450 human samples demonstrating acceptable levels of specificity and sensitivity. An estimated 7 mil. women suffer from endometriosis in the U.S. each year. Cytyc extended its women's health portfolio with a $325 mil. acquisition of NovaSure menorrhagia treatment manufacturer Novacept on March 1 (1"The Gray Sheet" March 8, 2004, p. 21)...
You may also be interested in...
Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment
Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.